INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ History of sensitivity to study medications or any │ History of sensitivity to study medications or any │     100 │
│ of their excipients                                │ of their excipients                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current treatment with antiplatelet therapy        │ Current treatment with antiplatelet therapy        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absolute indication for anti-platelet therapy      │ Absolute indication for anti-platelet therapy      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Need for chronic oral anticoagulant therapy        │ Need for chronic oral anticoagulant therapy        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe hepatic impairment (eg, ascites and/or      │ Severe hepatic impairment (eg, ascites and/or      │     100 │
│ clinical signs of coagulopathy)                    │ clinical signs of coagulopathy)                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A known bleeding diathesis, hemostatic or          │ A known bleeding diathesis, hemostatic or          │     100 │
│ coagulation disorder, or prior major bleeding      │ coagulation disorder, or prior major bleeding      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior stroke                                       │ Prior stroke                                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active pathological bleeding                       │ Active pathological bleeding                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of intracranial haemorrhage                │ History of intracranial haemorrhage                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant use of strong CYP 3A inhibitors or     │ Concomitant use of strong CYP 3A inhibitors or     │     100 │
│ inducers                                           │ inducers                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of thrombocytopenia or neutropenia         │ History of thrombocytopenia or neutropenia         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or nursing women, or females with a       │ Pregnant or nursing women, or females with a       │     100 │
│ positive pregnancy test at screening               │ positive pregnancy test at screening               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females of child bearing potential not using       │ Females of child bearing potential not using       │     100 │
│ acceptable method of birth control prior to or     │ acceptable method of birth control prior to or     │         │
│ during study                                       │ during study                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concern for inability of the patient to comply     │ Concern for inability of the patient to comply     │     100 │
│ with study procedures and/or follow up (eg,        │ with study procedures and/or follow up (eg,        │         │
│ alcohol or drug abuse)                             │ alcohol or drug abuse)                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of sensitivity to study medications or any │ History of sensitivity to study medications or any │     100 │
│ of their excipients                                │ of their excipients                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current treatment with antiplatelet therapy        │ Current treatment with antiplatelet therapy        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absolute indication for anti-platelet therapy      │ Absolute indication for anti-platelet therapy      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Need for chronic oral anticoagulant therapy        │ Need for chronic oral anticoagulant therapy        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe hepatic impairment (eg, ascites and/or      │ Severe hepatic impairment (eg, ascites and/or      │     100 │
│ clinical signs of coagulopathy)                    │ clinical signs of coagulopathy)                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A known bleeding diathesis, hemostatic or          │ A known bleeding diathesis, hemostatic or          │     100 │
│ coagulation disorder, or prior major bleeding      │ coagulation disorder, or prior major bleeding      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior stroke                                       │ Prior stroke                                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active pathological bleeding                       │ Active pathological bleeding                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of intracranial haemorrhage                │ History of intracranial haemorrhage                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of thrombocytopenia or neutropenia         │ History of thrombocytopenia or neutropenia         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or nursing women, or females with a       │ Pregnant or nursing women, or females with a       │     100 │
│ positive pregnancy test at screening               │ positive pregnancy test at screening               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females of child bearing potential not using       │ Females of child bearing potential not using       │     100 │
│ acceptable method of birth control prior to or     │ acceptable method of birth control prior to or     │         │
│ during study                                       │ during study                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concern for inability of the patient to comply     │ Concern for inability of the patient to comply     │     100 │
│ with study procedures and/or follow up (eg,        │ with study procedures and/or follow up (eg,        │         │
│ alcohol or drug abuse)                             │ alcohol or drug abuse)                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of osteoarthritis made by physician      │ OA cohort: Diagnosis of osteoarthritis made by     │      89 │
│                                                    │ physician                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anemia (hematocrit \< 27%)                         │ Anemia (hematocrit < 27%)                          │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count \< 100,000/ml                       │ Platelet count < 100,000/ml                        │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anemia (hematocrit \< 27%)                         │ Anemia (hematocrit < 27%)                          │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count \< 100,000/ml                       │ Platelet count < 100,000/ml                        │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal failure (eGFR \<30 or requiring dialysis)    │ Renal failure (eGFR <30 or requiring dialysis)     │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy \<12 months based on               │ Life expectancy <12 months based on investigator's │      99 │
│ investigator's judgement                           │ judgement                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients considered to be at risk of bradycardic   │ Patients considered to be at risk of bradycardic   │      99 │
│ events (e.g., known sick sinus syndrome or second  │ events (e.g., known sick sinus syndrome or second  │         │
│ or third degree atrioventricular \[AV)\] block)    │ or third degree atrioventricular [AV)] block)      │         │
│ unless already treated with a permanent pacemaker  │ unless already treated with a permanent pacemaker  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal failure (eGFR \<30 or requiring dialysis)    │ Renal failure (eGFR <30 or requiring dialysis)     │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy \<12 months based on               │ Life expectancy <12 months based on investigator's │      99 │
│ investigator's judgement                           │ judgement                                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                               │ CHIA Criteria                                      │   Score │
╞═════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ OA cohort                                       │ Anemia (hematocrit < 27%)                          │      35 │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ OA cohort                                       │ Anemia (hematocrit < 27%)                          │      35 │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years               │ Current treatment with antiplatelet therapy        │      37 │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ RA cohort                                       │ RA cohort: Previous intolerance to MTX             │      38 │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ RA cohort                                       │ RA cohort: Previous intolerance to MTX             │      38 │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Receiving MTX at stable doses of 10 to 25 mg    │ RA cohort: Receiving MTX at stable doses of 10 to  │      50 │
│ weekly for at least 12 weeks                    │ 25 mg weekly for at least 12 weeks, Have a DAS28   │         │
│                                                 │ of 3.2 or higher (The level of disease activity is │         │
│                                                 │ considered to be low if the DAS28 is 3.2 or less)  │         │
│                                                 │ (Prevoo et al., 1995)                              │         │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have a DAS28 of 3.2 or higher (The level of     │ RA cohort: Receiving MTX at stable doses of 10 to  │      76 │
│ disease activity is considered to be low if the │ 25 mg weekly for at least 12 weeks, Have a DAS28   │         │
│ DAS28 is 3.2 or less) (Prevoo et al., 1995)     │ of 3.2 or higher (The level of disease activity is │         │
│                                                 │ considered to be low if the DAS28 is 3.2 or less)  │         │
│                                                 │ (Prevoo et al., 1995)                              │         │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous intolerance to MTX                     │ RA cohort: Previous intolerance to MTX             │      83 │
╘═════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒═════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                               │ CHIA Criteria                                      │   Score │
╞═════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Have a DAS28 of 3.2 or higher (The level of     │ RA cohort: Receiving MTX at stable doses of 10 to  │      76 │
│ disease activity is considered to be low if the │ 25 mg weekly for at least 12 weeks, Have a DAS28   │         │
│ DAS28 is 3.2 or less) (Prevoo et al., 1995)     │ of 3.2 or higher (The level of disease activity is │         │
│                                                 │ considered to be low if the DAS28 is 3.2 or less)  │         │
│                                                 │ (Prevoo et al., 1995)                              │         │
├─────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous intolerance to MTX                     │ RA cohort: Previous intolerance to MTX             │      83 │
╘═════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 75
Average Levenshtein Ratio of individual lines: 89.93617021276596
OverAll Ratio: 82.46808510638297
